Research programme: antibody-based cancer immunotherapeutics - For-Robin

Drug Profile

Research programme: antibody-based cancer immunotherapeutics - For-Robin

Alternative Names: hJAA-F11; JAA-F11; JAA-F11 antibody; JAA-F11:DM1

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Buffalo
  • Developer For-Robin
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer

Most Recent Events

  • 24 Oct 2017 Research programme: antibody-based cancer immunotherapeutics - For-Robin is available for licensing as of 24 Oct 2017. http://www.for-robin.com/NeedOpp.html
  • 24 Oct 2017 Pharmacodynamic results from a preclinical study in Breast cancer released by For-Robin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top